InSysBio to present at PAGE 2018

events

Conference

May 24, 2018

May 24, 2018

InSysBio announces their participation at PAGE 2018 27th Meeting being held from 29 May to 1 June 2018 in Montreux, Switzerland. InSysBio welcomes visitors at the booth B1. InSysBio is also presenting four posters.

Wednesday, May 30 (10:10-11:40):

I-08: “A semi-mechanistic model of targeted therapy for melanoma” (view abstract) by Dmitrii Shchelokov and Oleg Demin Jr

Thursday, May 31 (09:55-11:30):

III-69: “Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology” (view abstract) by Tatiana Karelina, Alexander Stepanov and Oleg Demin
III-70: “Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study” (view abstract) by Oleg Demin Jr and Antonina Nikitich

Thursday, May 31 (15:10-16:40):

IV-35: “Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction” (view abstract) by Antonina Nikitich and Oleg Demin Jr

In addition, Etienne Pigeolet from Novartis will present a poster co-authored with InSysBio scientists Tatiana Karelina, Alexandra Urusova and Oleg Demin on Thursday, May 31 (15:10-16:40):

IV-59: “Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment” (view abstract)

About InSysBio

InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

←	December 2019	→
Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Upcoming Events

Mo	Tu	We	Th	Fr	Sa	Su
←	December 2019					→
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31